Lack of Specific Regulatory T Cell Depletion and Cytoreduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide.
Adam J Kleinman, Ranjit Sivanandham, Paola Sette, Egidio Brocca-Cofano, Colin McAndrews, Brandon F Keele, Ivona Pandrea, Cristian Apetrei
Article in AIDS research and human retroviruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 2 institutions in 1 country.
Adam J KleinmanDivision of Infectious Diseases, DOM, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ranjit SivanandhamDivision of Infectious Diseases, DOM, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Paola SetteDivision of Infectious Diseases, DOM, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Egidio Brocca-CofanoDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Colin McAndrewsDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Ivona PandreaDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cristian ApetreiDivision of Infectious Diseases, DOM, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-0322-7185
University of Pittsburgh · USFrederick National Laboratory for Cancer Research · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
SIV Pathogenesis in African Green Monkeys and Pigtailed MacaquesR01HL117715 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2012 to 2021
$7.0M
Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPsR01HL123096 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2015 to 2025
$6.8M
Assessing the Role of GI Tract Dysfunction to HIV/SIV Disease ProgressionR01DK113919 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRISTIAN APETREI, Ivona Vasile-Pandrea · 2017 to 2026
$5.7M
Immunology of Infectious DiseaseT32AI060525 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JoAnne L. Flynn · 2005 to 2026
$5.3M
New Strategy to Improve Gastrointestinal Health in SIV/HIVR01DK119936 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2018 to 2022
$5.1M
Animal Model for Testing SIV Latency Reversal StrategiesR01AI119346 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2015 to 2019
$3.4M
PITT AIDS RESEARCH TRAINING PROGRAMT32AI065380 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARRATT-BOYES, SIMON M · 2005 to 2020
Up to 93% of the human immunodeficiency virus (HIV) latent reservoir comprised defective proviruses, suggesting that a functional cure is possible through the elimination of a small population of cells containing intact virus, instead of the entire reservoir. Cyclophosphamide (Cy) is an established chemotherapeutic agent for immune cell cancers. In high doses, Cy is a nonselective cytoreductor, used in allogeneic stem-cell transplantation, while in a low dose, metronomic schedule, Cy selectively depletes regulatory T cells (Tregs). We administered low and high doses to simian immunodeficiency virus (SIV)-infected rhesus macaques (RM) to assess their effects on the SIV reservoirs. As a Treg-depleting agent, Cy unselectively depleted Treg and total lymphocytes, resulting in minimal immune activation and no viral reactivation. As a cytoreductive agent, Cy induced massive viral reactivation in elite controller RMs without ART. However, when administered with antiretroviral therapy (ART), Cy had substantial adverse effects, including mortality. Our study thus dissuades further investigation of Cy as an HIV cure agent.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lack of Specific Regulatory T Cell Depletion and Cytoreduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide. · full record | OpenQuestion